X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AK-OTOF is a dual adeno-associated viral (AAV) vector-based gene therapy intended to treat patients with OTOF-mediated hearing loss by delivering transgenes encoding OTOF to the inner hair cells (IHCs) of the cochlea.
Lead Product(s): AK-OTOF
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: AK-OTOF
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,097.0 million Upfront Cash: $1,097.0 million
Deal Type: Acquisition December 01, 2022
Details:
Proposed acquisition will accelerate gene therapies that aim to restore, improve, and preserve hearing for patients living with disabling hearing loss worldwide including lead product, AK-OTOF, a treatment of hearing loss due to mutations in the otoferlin gene.
Lead Product(s): AK-OTOF
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: AK-OTOF
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $487.0 million Upfront Cash: $487.0 million
Deal Type: Acquisition October 18, 2022
Details:
AK-OTOF is a dual adeno-associated viral (AAV) vector-based gene therapy intended to treat patients with OTOF-mediated hearing loss by delivering transgenes encoding OTOF to the inner hair cells (IHCs) of the cochlea.
Lead Product(s): AK-OTOF
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: AK-OTOF
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
Nonclinical data demonstrated that an AAVAnc80 vector led to durable restoration of auditory function and was well tolerated, supporting planned clinical development of AK-OTOF for treatment of OTOF-mediated hearing loss.
Lead Product(s): AK-OTOF
Therapeutic Area: Genetic Disease Product Name: AK-OTOF
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Details:
AK-OTOF is designed to treat underlying cause of OTOF-mediated hearing loss through delivery of a transgene using a dual vector technology that results in expression of normal, functional otoferlin protein in the affected cells, namely inner hair cells, in the cochlea.
Lead Product(s): AK-OTOF
Therapeutic Area: Genetic Disease Product Name: AK-OTOF
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
AK-OTOF and AK-antiVEGF, continue to advance preclinical development of potential gene therapies for inner ear conditions, such as GJB2-mediated hearing loss, and to develop platform capabilities that can be applied to regenerative medicine approaches in the inner ear.
Lead Product(s): AAVAnc80-antiVEGF Vector
Therapeutic Area: Rare Diseases and Disorders Product Name: AK-antiVEGF
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2022
Details:
AK-OTOF is designed to treat the underlying cause of OTOF-mediated hearing loss through delivery of a transgene using a dual vector technology that results in expression of normal, functional otoferlin protein in the affected cells, namely inner hair cells, in the cochlea.
Lead Product(s): AK-OTOF
Therapeutic Area: Genetic Disease Product Name: AK-OTOF
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2021
Details:
AK-OTOF is designed to treat the underlying cause of OTOF-mediated hearing loss through delivery of a transgene using a dual vector technology that results in expression of normal, functional otoferlin protein in the affected cells, namely inner hair cells, in the cochlea.
Lead Product(s): AK-OTOF
Therapeutic Area: Genetic Disease Product Name: AK-OTOF
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2021
Details:
Akouos' pipeline contains lead candidate AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the otoferlin gene.
Lead Product(s): AK-OTOF
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 05, 2020
Details:
Proceeds will be used to advance Akouos’s lead program, AK-OTOF, to first-in-human clinical studies subject to IND filing and to establish the company’s in-house GMP manufacturing capabilities.
Lead Product(s): AK-OTOF
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Pivotal bioVenture Partners
Deal Size: $105.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
